🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million instances annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the face of growing infection rates, the spread of superbugs and the highly restricted therapeutic options currently available.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a huge turning point in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

Based on data detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The study involved over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have voiced optimism. The availability of a one-pill regimen like this is hailed as a "game-changer" for public health efforts. This is deemed vital to lessen the impact of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.